Akoya Biosciences 2025 Q1 Earnings Misses Targets, Narrows Net Loss by 33%

Akoya Biosciences (AKYA) reported its fiscal 2025 Q1 earnings on May 13th, 2025. Akoya Biosciences reported first-quarter 2025 results with a 9.3% decline in revenue to $16.64 million, missing market expectations. The company did not offer earnings guidance, citing the pending acquisition by Quanterix Corporation as the reason for withholding future projections. Akoya’s financial performance has been pressured by macroeconomic challenges and NIH funding uncertainties. Nonetheless, operational discipline and innovation remain focal points as the company seeks to integrate with Quanterix and enhance its position in precision medicine.

Revenue
Akoya Biosciences reported a total revenue of $16.64 million for Q1 2025, marking a 9.3% decrease from the previous year. The product segment generated $12.03 million, with instruments contributing $5.03 million and consumables adding $6.94 million. Standalone software products contributed $58,000. Service and other revenue totaled $4.61 million, while the instrument warranty segment brought in $2.85 million.

Earnings/Net Income
Akoya Biosciences narrowed its loss to $0.32 per share in Q1 2025 from a $0.48 per share loss in Q1 2024, a 33.3% improvement. The net loss was reduced to $15.65 million, reflecting a 33.4% improvement from the previous year’s $23.48 million loss. This indicates a positive trend in reducing losses.

Post Earnings Price Action Review
The post-earnings price action strategy for Akoya Biosciences shows favorable outcomes when purchasing shares after a revenue miss and holding for 30 days. This approach has produced a 10.5% return, outperforming the SPY ETF’s 5.5% return over the same period. The strategy highlights the potential for short-term gains in Akoya's stock despite initial market reactions to revenue misses. This pattern suggests that investor sentiment may recover post-earnings, potentially driven by strategic prospects like the integration with Quanterix and ongoing advancements in the spatial biology sector. Despite initial stock declines, the strategy points to a resilient recovery potential for Akoya's shares in the short term.

CEO Commentary
“Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty,” said Brian McKelligon, CEO of Akoya Biosciences. He highlighted growing global momentum for their technology, marked by increased adoption in large-scale population studies and an expanding publication footprint in high-impact journals. McKelligon emphasized confidence in the upcoming integration with Quanterix, noting it as a significant opportunity to unite two leaders in proteomics and accelerate advancements in precision medicine.

Guidance
In light of the pending acquisition by Quanterix Corporation, Akoya will not be hosting an earnings conference call or providing forward-looking guidance at this time. The company has not offered specific projections or expectations regarding future performance or financial results in this report.

Additional News
In recent developments, Akoya Biosciences and Quanterix Corporation have announced an amended merger agreement, which aims to create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. This strategic merger is expected to accelerate the translation of biomarkers from research to clinical applications, driving new growth opportunities. Meanwhile, Akoya has expanded its biopharma service portfolio with the launch of a new ADC breast cancer assay and real-world IO60 insights at the AACR 2025 conference. Additionally, Akoya partnered with the Singapore Translational Cancer Consortium on the SUPER study, designed to advance cancer immunophenotyping for patients in Singapore, further solidifying its leadership in spatial biology solutions.